Exit interviews administered to patients participating in the COSTOP placebo controlled randomised trial in Uganda

World Health Organization, 2014 Anywaine, 2015, Safety of discontinuing Cotrimoxazole prophylaxis among HIV infected adults on anti-retroviral therapy in Uganda (COSTOP Trial): Design, Contemp. Clin. Trials, 43, 100, 10.1016/j.cct.2015.05.015 Smith, 2015 van der Straten, 2013, Evaluation of three approaches for assessing adherence to vaginal gel application in clinical trials, Sex. Transm. Dis., 40, 950, 10.1097/OLQ.0000000000000053 Pulford, 2014, The exit interview as a proxy measure of malaria case management practice: sensitivity and specificity relative to direct observation, BMC health Serv. Res., 14, 628, 10.1186/s12913-014-0628-8 Morrison-Beedy, 2013, Exit interviews from adolescent girls who participated in a sexual risk-reduction intervention: implications for community-based health education promotion for adolescents, J. Midwifery & Women’s Health, 58, 313, 10.1111/jmwh.12043 Munderi P, Levin JB, Anywaine Z, Kasirye R, Kamali A, Nunn AJ, et al. Is it Safe to Stop Cotrimoxazole in Adults on ART: COSTOP, a Noninferiority RCT. http://www.croiconference.org/sessions/it-safe-stop-cotrimoxazole-adults-art-costop-noninferiority-rct (accessed 05.01.15). Skoler-Karpoff, 2008, Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial, Lancet, 372, 1977, 10.1016/S0140-6736(08)61842-5